Continuing Education (continued from page 34) study, adults initiating pharmacological treatment for ADHD continued their medications for an average of only 50 days. Although early discontinuation of treatment commonly occurs in the care of adult ADHD, the factors that promote continuity of stimulant treatment remain largely unknown. Optimal management of ADHD includes pharmacologic and nonpharmacologic interventions. Support groups help persons of all ages with ADHD and their family members understand the disorder and available resources. Support groups can be located by calling an ADHD hotline (800.233.4050) or by contacting Children and Adults with Attention-Deficit/ Hyperactivity Disorder (CHADD) (Table 2). Other helpful websites on ADHD are also listed in Table 2. Summary and Conclusions Adult ADHD is one of the most common psychiatric disorders. It differs from ADHD in children and adolescents in that adults can often modify their daily routines to better match their temperament. It has been shown in most clinical trials that pharmacologic treatments effective in children and adolescents are also effective in adults. Although adults with ADHD are at higher risk for substance abuse than adults without the disorder, recent studies have shown that pharmacotherapy may reduce the risk of substance abuse in adults with ADHD. UAN #0100-0000-10-071-H01-P The content of this lesson was developed by the Ohio Pharmacists Foundation and reprinted with permission. No financial support was received for this activity. This
activity may appear in other state pharmacy association journals. Participants should not seek credit for duplicate content.
Meet me at the
Arizona Pharmacy Alliance 7th Annual Meeting July 7 – 10, 2011
Westin La Paloma Resort and Spa
Register Now at the Early Bird Rate! ix, hoen
May
• P 011 2 , 1-4
ona Ariz
The College of Psychiatric and Neurologic Pharmacists (CPNP) is a professional association of psychiatric and neurologic pharmacists. The CPNP Annual Meeting offers cutting-edge information ideal for the pharmacist, physician, nurse practitioner or other healthcare professional involved in the medication therapy management of psychiatric and/or neurologic patients.
Meeting Highlights Include: Pre-Meeting Workshop: A 3-hour workshop on Optimizing Cardiovascular Health in Psychiatric Patients will be offered on May 1. This workshop will provide hands-on experience in selecting first-line agents, identifying adverse effects and monitoring techniques to maintain safe and adequate care. Daily Keynote Addresses From: • Seizing the MTM Opportunity Linda Strand, PharmD, PhD • Drug Transporters and Psychiatry Lindsay Devane, PharmD, BCPP, FCCP • Management of Aggression in Children Lynn Crismon, PharmD, BCPP, FCCP • Glutamate: The Emerging Frontier of Psychopharmacology - Stephen Stahl, MD, PhD Programming: Registrants have 23 hours of ACPE and CME approved programming to choose from along with an anticipated five industry supported symposia opportunities. Research: Three hours of the meeting will be dedicated to networking with an anticipated 150+ poster authors. Abstract and Award submissions are open to all investigators with submissions due January 12, 2011.
Tucson, Arizona Registration and information available at cpnp.org/2011